Chile Faces Urgent Need for Sustainable Funding for Rare Disease Treatments
Families in Chile are facing a long-standing crisis regarding access to treatments for rare diseases, a situation recently highlighted by discussions in the Chamber of Deputies' Health Commission. The reliance on judicialization as a solution has proven insufficient and is no longer providing answers, especially after recent rejections by the Supreme Court. This necessitates the urgent development of mechanisms for timely, equitable, and sustainable access to these vital treatments. The national health expenditure through judicial rulings has dramatically increased, projected to jump from 22.947 billion Chilean pesos in 2020 to nearly 90 billion pesos by 2025, underscoring the critical need for efficient public resource management tools. Paulina González, President of FAME Chile, presented this reality to the Health Commission on July 7th, representing affected families. The case of Spinal Muscular Atrophy (SMA), a severe neuromuscular condition and the leading genetic cause of infant mortality, exemplifies the current state of helplessness. In 2024 alone, the state spent 18 billion Chilean pesos on judicializing the three SMA drugs, accounting for 22.5% of the entire national budget allocated for high-cost therapy lawsuits. Access to treatments remains a significant and pressing issue that Chile cannot afford to postpone further.
The increasing reliance on judicial processes to secure funding for rare disease treatments in Chile, as evidenced by the surge in health expenditure through court rulings, indicates a systemic failure in public health policy. While judicialization offered a temporary recourse, its limitations and recent Supreme Court rejections reveal the unsustainability of this approach. The significant portion of the national budget dedicated to legal battles for high-cost therapies, such as those for Spinal Muscular Atrophy (SMA), suggests a misallocation of resources that could be more efficiently managed through proactive, established funding mechanisms. Moving forward, Chile must prioritize developing integrated policies that ensure equitable and sustainable access to treatments, thereby reducing the burden on families and the public purse, and aligning healthcare provision with long-term public health objectives.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.